首页> 美国卫生研究院文献>The Oncologist >Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

【2h】

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

机译：CapOX加贝伐单抗和CapIRI加贝伐单抗的II期随机试验作为日本转移性大肠癌患者的一线治疗（CCOG-1201研究）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

获取外文期刊封面目录资料

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Purpose.The aim of this randomized, multicenter, noncomparative, phase II trial was to investigate the efficacy and safety of two potential first‐line treatments, capecitabine and oxaliplatin (CapOX) plus bevacizumab (BEV) and capecitabine and irinotecan (CapIRI) plus bevacizumab, in Japanese patients with metastatic colorectal cancer (mCRC).

机译：目的：这项随机，多中心，非比较性II期临床试验的目的是研究两种潜在的一线治疗卡培他滨和奥沙利铂（CapOX）加贝伐单抗（BEV）和卡培他滨和伊立替康（CapIRI）加贝伐单抗的疗效和安全性在日本患有转移性大肠癌（mCRC）的患者中。

著录项

期刊名称 The Oncologist
作者
Goro Nakayama; *; Ayako Mitsuma; Yuki Sunagawa; Kiyoshi Ishigure; Hiroyuki Yokoyama; Takanori Matsui; Hiroshi Nakayama; Kazuhiko Nakata; Akiharu Ishiyama; Takahiro Asada; Shinichi Umeda; Kazuhiro Ezaka; Norifumi Hattori; Hideki Takami; Daisuke Kobayashi; Chie Tanaka; Mitsuro Kanda; Suguru Yamada; Masahiko Koike; Michitaka Fujiwara; Tsutomu Fujii; Kenta Murotani; Yuichi Ando; Yasuhiro Kodera;
展开▼
作者单位

展开▼
年(卷),期 2018(23),8
年度 2018
页码 919–927
总页数 9
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Metastatic colorectal cancer Capecitabine Irinotecan Oxaliplatin Bevacizumab UGT1A1;

机译：转移性结直肠癌;卡培他滨;伊立替康;奥沙利铂;贝伐单抗;UGT1A1;

相似文献

外文文献
中文文献
专利

1. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study) [J] . Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, The oncologist . 2018,第8期

机译：Capox Plus Bevacizumab和Capiri Plus Bevacizumab的随机阶段II试验作为日本转移性结肠直肠癌患者的一线治疗（Ccog-1201研究）
2. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as Firsta??Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOGa??1201 Study) [J] . Goro Nakayama, Ayako Mitsuma, Yuki Sunagawa, The oncologist . 2018,第8期

机译：CapOX加贝伐单抗和CapIRI加贝伐单抗的II期随机试验作为日本转移性结直肠癌患者的Firsta？line治疗（CCOGa ?? 1201研究）
3. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [J] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, BMC Cancer . 2011,第1期

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机，III期试验：AIO KRK 0110 Trial / ML22011试验
4. Correlation between development of hypertension and efficacy in metastatic colorectal cancer patients treated with bevacizumab [C] . Horinouchi Y., Sakurada T., Nakamura T., European Association for Clinical Pharmacology and Therapeutics . 2011

机译：北伐单抗治疗转移性结直肠癌患者高血压与疗效的相关性
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. A randomized phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Clemens Giessen, Ludwig Fischer von Weikersthal, Axel Hinke, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验
7. A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial [O] . Teschendorf Christian, Sieber Markus, Denzlinger Claudio, 2011

机译：卡培他滨加贝伐单抗（Cape-Bev）与卡培他滨加伊立替康+贝伐单抗（CAPIRI-Bev）在转移性结直肠癌一线治疗中的随机III期试验：AIO KRK 0110 Trial / ML22011试验

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅